Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on March 22, 2024. The report addresses a specific corporate event regarding the company's compliance status with the NYSE American listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes
- Regulatory Compliance: On March 21, 2024, the Company received notification from the NYSE American LLC that it has regained compliance with the continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide.
- Reason for Compliance: The regained compliance is attributed to the Company's shares of common stock demonstrating sustained price improvement.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the Company's strategic focus, the development of product candidates (including MAT2203), and anticipated regulatory timelines. Management highlights several material risks, including:
- The ability to obtain additional capital to meet liquidity needs and complete clinical trials.
- Uncertainties inherent in clinical testing and the timing of regulatory approvals.
- Intellectual property protection and competition.
- Changes in the regulatory landscape.
The Company notes that all product candidates remain in the development stage and are not currently available for sale.
Investor Verification Checklist
- Verify the current stock price trend to confirm the "sustained price improvement" cited as the basis for regained listing compliance.
- Review the attached Press Release (Exhibit 99.1) for detailed commentary on the compliance letter.
- Check recent 10-Q or 10-K filings for updated liquidity positions and cash burn rates, as this 8-K does not contain financial figures.
- Monitor upcoming clinical trial milestones for MAT2203 and other product candidates mentioned in the forward-looking statements.